TCGA-OR-A5K0-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.234
- MITOTIC_SPINDLE+0.189
- G2M_CHECKPOINT+0.172
- HEDGEHOG_SIGNALING+0.169
- PANCREAS_BETA_CELLS+0.165
- WNT_BETA_CATENIN_SIGNALING+0.129
- MYC_TARGETS_V1+0.124
- MYC_TARGETS_V2+0.111
- ESTROGEN_RESPONSE_EARLY+0.088
- XENOBIOTIC_METABOLISM+0.085
Top 10 suppressed
- ANGIOGENESIS-0.382
- KRAS_SIGNALING_UP-0.336
- NOTCH_SIGNALING-0.308
- ALLOGRAFT_REJECTION-0.242
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.222
- CHOLESTEROL_HOMEOSTASIS-0.191
- UV_RESPONSE_DN-0.178
- IL2_STAT5_SIGNALING-0.175
- OXIDATIVE_PHOSPHORYLATION-0.167
- ANDROGEN_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-04162 | — | cohortSQ2 | 0.672 |
| 2 | TCGA-56-7221-01A-11R-2045-07 | — | cohortSQ2 | 0.655 |
| 3 | BS_4D9DD103 | medulloblastoma | — | 0.649 |
| 4 | 19-001pA3-U | — | — | 0.642 |
| 5 | sclcM1141057A2_S62.txt | — | cohortSC | 0.638 |
| 6 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.637 |
| 7 | TCGA-85-8580-01A-31R-2403-07 | — | cohortSQ2 | 0.637 |
| 8 | MDT-AP-0340 | Med | Medulloblastoma | 0.636 |
| 9 | TCGA-22-4601-01A-01R-1443-07 | — | cohortSQ2 | 0.635 |
| 10 | 482876d9-a6fb-4642-acbc-c3e45880e576 | — | — | 0.635 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.234 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.189 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.172 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.169 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.165 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.129 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.124 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.111 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.088 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.085 | Inavolisib | — uncovered |
| HYPOXIA | 0.083 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.077 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.074 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.074 | Idelalisib | — uncovered |
| PEROXISOME | 0.061 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.059 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.048 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.042 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.032 | Inavolisib | — uncovered |